Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab for Recent-Onset Type 1 Diabetes
NCT03941132Phase 3Active, not recruiting
- Sponsor
- University of British Columbia
- Start
- Jan 2021
- Primary completion
- Feb 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ustekinumab in type 1 diabetes mellitus (T1D), sponsored by University of British Columbia. Started Jan 2021; status: active, not recruiting.
02
Drugs
ustekinumab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03941132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03941132.